Best Practice in Biological Sample Collection, Processing, and Storage for LC-MS in Bioanalysis of Drugs

Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations

Volumn , Issue , 2013, Pages 139-164

  Pawula, Maria ^a   Hawthorne, Glen ^a   Smith, Graeme T ^a   Hill, Howard M ^a  

^a HUNTINGDON LIFE SCIENCES   (United Kingdom)

Author keywords

Adsorption; Aggregation; Biological sample collection; Drugs; LC MS bioanalysis; Sample processing and handling; Sample storage; Sample transportation; Stabilizers

Indexed keywords

ADSORPTION; AGGLOMERATION; CHEMICAL ANALYSIS; EMPENNAGES; PROTEINS; SHIPS;

BIOANALYSIS; BIOLOGICAL SAMPLES; DRUGS; SAMPLE PROCESSING; SAMPLE STORAGE;

DIGITAL STORAGE;

EID: 85007041694     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118671276.ch13     Document Type: Chapter

References (86)

1. Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis 2009; 1(1):205-220.
2. Burtis CA, Ashwood RE, Bruns DE. Tietz Fundamentals of Clinical Chemistry. 5th ed. Philadelphia, PA: Saunders; 2001.
3. Bush V. Why doesn't my heparinized plasma specimen remain anticoagulated?: A discussion on latent fibrin formation in heparinized plasma. LabNotes 2003;13(2):9-14.
4. Buskin JN, Upton RA, Williams RL. Improved liquid chromatography of aspirin, salicylate, and salicylic acid in plasma, with a modification for determining aspirin metabolites in urine. Clin Chem 1982;28:1200-1203.
5. Cao YG, Zhang M, Yu D, Shao JP, Chen YC, Liu XQ. A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimised solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study. Anal Bioanal Chem 2008;391(3): 1063-1071.
6. Chang Q, Chow MS, Zuo Z. Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method. Biomed Chromatogr 2009;23(8):852-857.
7. Chen C, Bajpai L, Mollova N, Leung K. Sensitive and cost-effective LC-MS/MS method for quantitation of CVT-6883 in human urine using sodium dodecylbezenesulfonate additive to eliminate adsorptive losses. J Chromatogr B 2009;877:943-947.
8. Chen J, Hsieh Y. Stabilizing drug molecules in biological samples. Ther Drug Monit 2005;27:617-624.
9. Chow FI, Omeye ST. Use of antioxidants in the analysis of vitamins A and E in mammalian plasma by high performance liquid chromatography. Lipids 1983;18(11):837-841.
10. Chung WY, Chung JK, Szeto YT, Tomlinson B, Benzie IF. Plasma ascorbic acid: measurement, stability and clinical utility revisited. Clin Biochem 2001;34(8):623-627.
11. D'Arienzo CJ, Ji QC, Discenza L, et al. DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis 2010;2(8):1415-1422.
12. Dell D. Labile metabolites. Chromatographia 2004;59:S139-S148.
13. EC 2006 Guidance document for GLP inspectors and GLP test facilities: Cross-contamination of control samples with test item in animal studies. Available at http://ec.europa.eu/enterprise/sectors/chemicals/files/glp/guidance:xcont_final _18_01_2006.en.pdf. Accessed Mar 14, 2013.
14. EMA Guideline on bioanalytical method Validation. Adopted July 2011, Effective February 2012. Available at www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed Mar 14, 2013.
15. El Mahjoub A, Staub C. Stability of benzodiazepines in whole blood samples stored at varying temperatures. J Pharm Biomed Anal 2000;23:1057-1063.
16. Elsayed NM, Ryabik JR, Ferraris S, Wheeler CR, Korte DW. Determination of physostigmine in plasma by high-performance liquid chromatography and fluorescence detection. Anal Biochem 1989;177(1):207-211.
17. Evans C. The application of Dried Blood Spots for quantitation of xenobiotics-a paradigm shift within Pre-clinical DMPK. Presentation given on Feb 11, 2010, at Delaware Valley, Drug Metabolism Discussion Group meeting.
18. FDA presentation by J. A. O'Shaughnessy. Bioequivalence and Good Laboratory Practice. Available at www.fda.gov/downloads/Drugs/NewsEvents/ucm182564.pdf. Accessed Mar 14, 2013.
19. FDA. Guidance for Industry: Safety Testing of Drug Metabolites. February 2008. Available at www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf. Accessed Mar 14, 2013.
20. Fu Y, Li W, Smith HT, Tse FLS. An investigation of incurred human urine sample analysis failure. Bioanalysis 2011;3(9):967-972.
21. Fung EN, Zheng N, Arnold ME, Zeng J. Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS. Bioanalysis 2010;2(4):733-743.
22. Fura A, Harper TW, Zhang H, Fung L, Shyu WC. Shift in pH of biological fluids during storage and processing: effect on Bioanalysis. J Pharm Biomed Anal 2003;32(3):513-522.
23. Gataye Perez A. Can dried blood spot technique be used to stabilize pro-drugs and glucuronides metabolites? EBF workshop: Connecting Strategies on Dried Blood Spots, June 17-18, 2010, Brussels, Belgium.
24. Green JH. Basic Clinical Physiology. 3rd ed. Oxford: Oxford University Press; 1978.
25. Guder WG, Narayanan S,Wisser H. et al. Samples: From the Patient to the Laboratory: The Impact of Preanalytical Variables on the Quality of Laboratory Results. Darmstadt: GIT; 1996. p 1-149.
26. Heilbronn E. Action of fluoride on cholinesterases. I on the mechanism of inhibition. Acta Chem Scand 1965;19:1333-1346.
27. Hersberger M, Nusbaumer C, Scholer A, Knopfli V, Von Eckardstein A. Influence of practicable virus inactivation procedures on tests for frequently measured analytes in plasma. Clinical Chemistry 2004;50(5):944-946.
28. IATA. First published in 2005. Guidelines for shipment of samples. Available at www.iata.org. Accessed Mar 14, 2013.
29. Itkin A, Dupres V, Dufrene YF, et al. Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS 2011;6(3):e18250. doi.10.1371/journal.pone.0018250.
30. International conference on Harmonisation of technical requirements for registration of Pharmaceuticals for Human Use. ICH Topic M3 (R2) Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals. 2009. Available at www.ichorg/LOB/media/MEDIA5544.pdf. Accessed Mar 14, 2013.
31. Jemal M, Ouyang Z, Chen BC, Teitz D. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high performance liquid chromatography with electrospray tandem mass spectrometry. Rapid comm. Mass Spec 1999;13(11):1003-1011.
32. Jemal M, Xia YQ. Bioanalytical method validation design for the simultaneous quantitation of analytes that may undergo interconversion during analysis. J Pharm Biomed Anal 2000;22(5):813-827.
33. Jemal M, Khan S, Teitz DS, McCafferty JA, Hawthorne DJ. LCMS/MS determination of omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor, and its sulfhydryl- and thioethercontaining metabolites in human plasma. Analytical Chemistry 2001;73(22):5450-5456.
34. Jewell C, Ackermann C, Payne NA, Fate G, Voormann R, Williams FM. Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver. Drug Metab Dispos 2007;35(11):2015-2022.
35. Ji JA, Jiang Z, Livson Y, Davis JA, Chu JX, Weng N. Challenges in urine bioanalytical assays: overcoming nonspecific binding. Bioanalysis 2010;2(9):1573-1586.
36. Kale P, Sharma R, Gupta RK, Modi S, Patidar K, Hussain S. Stability study of Diltiazem and its major metabolite in human plasma. Poster at the 2010 AAPS Annual Meeting on November 14-18, 2010, New Orleans, USA. Abstract. Available at www. AAPSJ.org/abstracts/AM_2010/T2278.pdf. Accessed Mar 14, 2013.
37. Kraut A, Marcellin M, Adrait A, Kuhn L, Louwagle M, Keifer-Jaquinod S, et al. Peptide storage: are you getting the best return on your investment? Defining optimal storage conditions for proteomics samples. J Proteome Res 2009;8:3778-3785.
38. Kudo S, Umehara K, Hosokawa M, Miyamot G, Chiba K, Satouh T. Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation. J Pharmacol Exp Ther 2000;294(1):80-87.
39. Lakshmy R. Analysis of the use of Dried Blood Spot Measurements in Disease Screening. J Diabetes Sci Technol 2008;2(2);242-243.
40. Liang H, Vahid M, Zhu Y, et al. Determination of Acetylsalicylic acid in Human Plasma by LC-MS/MS. Proceedings of the 57th ASMS Conference of Mass Spectrometry 1-4 June 2009 Philadelphia, PA.
41. Lindegardh N, Davies G, Hien TT, et al. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother 2006;50(9):3197-3199.
42. Lindegardh N, Davies G, Hien TT, et al. Importance of collection tube during clinical studies of Oseltamivir. Antimicrob Agents Chemother 2007;51(5):1835-1836.
43. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Sem Thromb Hem 1999;3:5-16.
44. Lippi G, Salvangno GL, Montagnana M, Poli G, Giudi GC. Influence of centrifuge temperature on routine coagulation testing. Clin Chem 2006;52(3):537-538.
45. Li W, Luo S, Smith HT, Tse FLS. Quantitative determination of BAF312, a S1P-R modulator, in human urine by LC-MS/MS: Prevention and recovery of lost analyte due to container surface adsorption. J Chromatogr B 2010;878:583-589.
46. Luo W, Zhu L, Deng J, Lui A, Guo B, Tan W, Dai R. Simultaneous analysis of bambuterol and its active metabolite terbutaline enantiomers in rat plasma by chiral liquid chromatographyomatographs spectrometry. J Pharm Biomed Anal 2010;52(2):227-231.
47. Li W, Zhang J, Tse FLS. Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr 2011;25:258-277.
48. Moore DE. Photophysical and photochemical aspects of drug stability. In: Tonnesen HH, editor. Photostability of Drugs and Drug Formulations. Boca Raton, FL: CRC Press; 2004. Chapter 2, p 9-40.
49. Murphy-Poulton SF, Boyle F, Gu XQ, Mather LE. Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP. J Chromatogr B 2006;831(1-2):48-56.
50. Narayanan S. Effect of anticoagulants used for blood collection on laboratory tests. Jpn J Clin Pathol 1996;103:73-80.
51. Narayanan S, Hamasaki N. Current concepts of coagulation and fibrinolysis. Adv Clin Chem 1998;33:133-168.
52. NHS guidance and best practice documents. Available at www.nhs.uk.
53. Osselton MD. The release of basic drugs by the enzymic digestion of tissues in cases of Poisoning. J Forens Sci Soc 1977;17(2):189-194.
54. Parker MH, Reitz AB. Assembly of β-Amyloid aggregates at the molecular level. Chemtracts-Organic Chemistry 2000; 13(1):51-56.
55. Pearlman R, Bewley TA. Stability and characterisation of human growth hormone, Chapter 1. In: Wang YJ, Pearlman R, editors. Stabilisation and Characterisation of Protein and Peptide Drugs. Pharmaceutical Biotechnology. Volume 5. New York: Plenum Press; 1993.
56. Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques best practice and research. Clin Haematol 2006;19(1):205-242.
57. Priston MJ, Sewell GJ. Improved LC assay for the determination of mitozantrone in plasma: analytical considerations. J Pharm Biomed Anal 1994;12:1153-1162.
58. Rang HP, Dale MM. Haemostasis and thrombosis. Chapter 16. In: Pharmacology. 2nd ed. Edingburgh: Churchill Livingstone; 1991.
59. Richterich R, Columbo JP. Clinical Chemistry: Theory, Practice and Interpretation. Translated edition. Chichester: John Wiley & Sons Ltd; 1981.
60. Sadagopan NP, Li W, Cook JA, et al. Investigation of EDTA anticoagulant in plasma to improve the throughput of liquid chromatography/tandem mass spectrometric assays. Rapid Comm Mass Spec 2003;17(10):1065-1070.
61. Saxer C, Niina M, Nakashima A, Nagae Y, Masuda N. Simultaneous determination of levodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemicaldetection. J Chromatogr B 2004;802(2):299-305.
62. Sennbro CJ, Knutsson M, Amsterdam P, Timmermann P. Anticoagulant counter ion impact on bioanalytical LC-MS/MS assays: results from discussion and experiments within the European Bioanalytical Forum. Bioanalysis 2011;3(21):2393-2399.
63. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003;25(1):1-16.
64. Silvester S. Strategy for over-coming non-specific analyte adsorption issues in clinical urine samples: Consideration of bioanalysis and metabolite identification. Oral presentation at 6th Bioanalysis in Clinical Research event Feb 15-16, 2011.
65. Skopp G, Klingman A, Pötsch L, Mattern R. In vitro stability of cocaine in whole blood and plasma including ecgonine as a target analyte. Ther Drug Monit 2001;23(2):174-181.
66. Sofer G, Lister DC, Boose JA. Virus inactivation in the 1990s-and into the 21st century: Part 6, inactivation methods grouped by virus. BioPharm International 2003; 16(4), 42-52, 68.
67. Srinivasan K, Nouri P, Kavetskala O. Challenges in the indirect quantitation of acyl-glucuronide metabolites of a cardiovascular drug from complex biological mixtures in the absence of reference standards. Biomed Chromatogr 2010;24(7):759-767.
68. Stout PR, Horn CK, Lesser DR. Loss of THCCOOH from urine specimens stored in polypropylene and polyethylene containers at different temperatures. J Anal Toxicol 2000;24(7):567-571.
69. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 2009;39(5):391-398.
70. US FDA 2000. Compliance Program Guidance Manual. Attachment A Bioequivalence Inspection Report. Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/guidances. Accessed Mar 14, 2013.
71. US FDA. 2001. Guidance for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. Available at www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070107.pdf. Accessed Mar 14, 2013.
72. Wang X, Bowman PD, Kerwin SM, Stavchansky S. Stability of caffeic acid phenethyl ester and its fluronated derivative in rat plasma. Biomed Chromatogr 2007;21(4):434-350.
73. Wang YJ, Pearlman R, editors. Stabilisation and Characterisation of Protein and Peptide Drugs. Pharmaceutical Biotechnology Volume 5. New York: Plenum Press; 1993.
74. Waters. ESI+ Common Background Ions. Available at www.waters.com/webassets/cms/support/docs/bkgrnd_ion_mstr_list.pdf. Accessed Mar 14, 2013.
75. Watt AP, Morrison D, Locker KL, Evans DC. Higher throughput bioanalysis by automation of a protein precipitation assay using a 96-well plate format with detection by LC-MS/MS. Anal Chem 2000;72(5):979-984.
76. WHO. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924, 2004.
77. WHO. Guidelines on drawing blood: best practices in phlebotomy. Geneva: WHO Press. 2010.
78. Wyss R, Bucheli F. Determination of of cefetamet and its orally active ester, cefetamet pivoxil, in biological fluids by high performance liquid chromatography. J Chromatogr B 1988;430:81-92.
79. Xu Y, Keith B, Grem JL. Measurement of the anticancer agent gemcitabine and its deaminated metabolite at lowconcentrations in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B 2004;802(2):263-270.
80. Xu Y, Du L, Rose MJ, Fu I, Woolf EJ, Musson DG. Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine. J Chromatogr B 2005;818(2):241-248.
81. Yamouri S, Fujiyama N, Kushihara M, et al. Involvement of human blood arylesterases and liver microsomal carboxylesterase in nafamostat hydrolysis. Drug Metab Pharmacokinet 2006;21(2):147-155.
82. Yapa U, Ionita I, Steenwyk RC. Improve the stability of unstable compounds in blood using dry blood spotting (DBS) technique followed by LC-MS/MS analysis. Proceedings of the 58th ASMSConference on Mass spectrometry and allied Topics, May 23-27, 2010, Salt Lake City, UT.
83. Zhang JG, Fariss MW. Thenoylfluoroacetone, a potent inhibitor of carboxylesterase activity. Biochem Pharmacol 2002;63:751-754.
84. Zhang N, Yang A, Rogers JD, Zhao JJ. Quantitation of simvastatin and its β-hydroxy acid in human plasma by using automated liquid-liquid extraction based on 96-well plate format and liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2004;34(1):175-187.
85. Zhao B, Moochhala SM, Lu J, Tan D, Lai MH. Determination of pyridostigmine bromide and its metabolites in biological samples. J Pharm Pharmacet Sci 2006;9(1):71-81.
86. Zhao JJ, Xie JH, Yang AY, Roadcap BA, Rodgers JD. Quantitation of simvastatin and its β-hydroxy acid in human plasma by liquidliquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrometr 2000;35:1133-1143.